Sangamo Therapeutics, Inc.
SGMO
$0.6213
-$0.0856-12.11%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 62.01% | 45.96% | -25.78% | -157.97% | -34.09% |
| Total Depreciation and Amortization | -57.82% | -58.43% | -30.63% | -9.75% | 7.93% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.31% | -88.46% | -47.45% | 31.09% | 474.95% |
| Change in Net Operating Assets | 102.75% | 94.50% | 95.72% | 93.38% | -99.27% |
| Cash from Operations | 70.14% | 50.58% | 27.05% | 10.28% | -0.54% |
| Capital Expenditure | 98.74% | 89.27% | 80.40% | 60.21% | -4.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -79.48% | -58.67% | -13.62% | 36.21% | 119.85% |
| Cash from Investing | -75.56% | -53.35% | 3.68% | 64.66% | 158.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.37% | -35.95% | -71.38% | -69.26% | -81.51% |
| Repurchase of Common Stock | 6.54% | 23.22% | 31.33% | 52.54% | 30.94% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 94.52% | -36.53% | -72.19% | -69.53% | -82.77% |
| Foreign Exchange rate Adjustments | -238.10% | 71.49% | -107.84% | -68.12% | 18.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.05% | 54.51% | 20.31% | 41.91% | 29.57% |
